Skip to main content
Arctic Bioscience logo

Arctic Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · NO0010859580 LEI · 549300Z2HW6I989Q2C78 OL Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2024-10-15 Director's Dealing
Country NO Norway
Listing OL ABS

About Arctic Bioscience

https://arctic-bioscience.com/

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical and nutraceutical products derived from marine membrane lipids. The company utilizes proprietary technology to extract bioactive compounds from herring roe, sourced from sustainable, MSC-certified fisheries. Its nutraceutical product line, marketed under the brand name Romega, consists of high-DHA Omega-3 phospholipid extracts. The pharmaceutical division is focused on developing a novel drug candidate for the treatment of mild-to-moderate psoriasis, aligning with its mission to create therapies for autoimmune disorders. The company's work is supported by extensive research and development to validate the efficacy of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Arctic Bioscience - Meldepliktig handel
Director's Dealing Classification · 98% confidence The document text is a short announcement in Norwegian titled "Arctic Bioscience - Meldepliktig handel" (Mandatory Trading). It details a purchase of shares by a related party (Gold Coast Nutrition, owned by the CSO) in Arctic Bioscience. The text explicitly mentions that this information is subject to disclosure under MAR (Market Abuse Regulation) Article 19 and the Securities Trading Act § 5-12, which governs insider trading and transactions by persons discharging managerial responsibilities (PDMRs). This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). The code for this is DIRS.
2024-10-15 Norwegian
Arctic Bioscience - Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is titled "Arctic Bioscience - Mandatory notification of trade" and explicitly states that a person closely associated with a person discharging managerial responsibility (CSO) has bought shares. It references disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19, which governs insider transactions. This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors).
2024-10-15 English
Arctic Bioscience - Invitation to webcast - HeROPA read-out
Report Publication Announcement Classification · 99% confidence The document is a short announcement inviting recipients to a webcast scheduled for October 16, 2024, to present results from the 'HeROPA clinical trial read-out'. It provides webcast details (date, time, link) and contact information. It is not the full financial report (10-K, IR), nor is it a formal earnings release (ER) which typically contains key figures. It is an announcement about an event where results will be discussed. Since it is an announcement regarding the presentation of results, and it doesn't fit perfectly into the specific categories like DIV, DVA, or ER, it is best classified as a general Regulatory Filing (RNS) or potentially a Call Transcript (CT) if the webcast were the transcript itself. However, since it is an *invitation* to a future event (webcast), and the content is primarily logistical and promotional for that event, RNS (Regulatory Filings) serves as the most appropriate general regulatory announcement category, as it is a required disclosure under securities law ('section 5-12 of the Norwegian Securities Trading Act'). Given the context of presenting clinical trial results, it is a specific type of corporate update that doesn't map cleanly to the provided options other than the general regulatory bucket.
2024-10-15 English
Arctic Bioscience - Invitasjon til webcast - HeROPA utlesning
Report Publication Announcement Classification · 99% confidence The document is an invitation ('Invitasjon til webcast') for a presentation regarding the results of the HeROPA clinical study, scheduled for a specific date and time. It provides details on how to access the webcast (link, time, format) and names the presenters (CEO and CMO). This type of announcement, which schedules a call to discuss results or strategy, most closely aligns with an Investor Presentation (IP) or potentially an Earnings Release (ER) if the results were financial. However, since it is explicitly inviting participants to a live presentation/webcast to discuss study results, it functions as an Investor Presentation or a precursor to a Call Transcript (CT). Given the context of presenting study results to investors via a webcast, 'Investor Presentation' (IP) is the most fitting category, as it is a planned event to convey specific company information to the investment community, distinct from a formal earnings release (ER) or a transcript of a call already held (CT). It is not a formal regulatory filing like 10-K or AR, nor is it a general announcement of a report release (RPA).
2024-10-15 Norwegian
Arctic Bioscience - Announces top-line results from the phase 2b HeROPA study
Earnings Release Classification · 100% confidence The document is titled 'Arctic Bioscience - Announces top-line results from the phase 2b HeROPA study' and details the outcome of a clinical trial (Phase 2b) for a drug candidate (HRO350). It discusses endpoints (PASI50), safety, and future plans, which are typical components of an Earnings Release (ER) or a specific clinical update. Since it is an announcement of preliminary/top-line results rather than the full, comprehensive financial report (10-K) or a detailed management discussion (MDA), the most appropriate classification is Earnings Release (ER). The document also mentions that a webcast will present the findings, indicating this text serves as the initial public disclosure of performance metrics for the period/study. Q4 2024
2024-10-14 English
Arctic Bioscience - New cellular research showing anti-psoriatic effects
Regulatory Filings Classification · 90% confidence The document is a short press release announcing new cellular research findings related to the investigational medicinal product HRO350, presented at the EADV congress. It includes quotes from the CEO and Medical Director, references to ongoing clinical trials, and contact information. It is not a full financial report (10-K, IR), a transcript (CT), or a formal dividend/share change notice. Since it is an announcement of new scientific/research data that doesn't fit the specific categories like ER, AR, or SR, and it is a general corporate update, it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory/corporate announcement, or potentially an Investor Presentation (IP) if it were a slide deck, but given the format, RNS is the most appropriate fallback for a general corporate update/news release that isn't a core financial filing or specific event announcement.
2024-09-25 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.